ATHE Alterity Therapeutics Limited

SCHEDULE 13D

* The 238,105,533 Ordinary Shares referenced herein are evidenced by 3,968,425 American Depositary Shares (“ADSs”). Each ADS represents sixty (60) Ordinary Shares.

** This calculation is based on information publicly provided by the Issuer that 2,406,874,578 Ordinary Shares, including Ordinary Shares evidenced by ADSs, were outstanding as of December 31, 2021.

This Amendment No. 7 to Schedule 13D (the “Amendment”) is being filed by Life Biosciences LLC, a limited liability company organized under the laws of Delaware (the “Reporting Person” or “Life”), to amend the Statement on Schedule 13D originally filed with the Securities and Exchange Commission on April 18, 2019, as amended on December 23, 2019, July 6, 2020, October 23, 2020, November 24, 2020, July 8, 2021 and March 4, 2022 (the “Schedule 13D”), with respect to the ordinary shares (the “Ordinary Shares”) of Alterity Therapeutics Limited (the “Issuer”).

Unless specifically amended hereby, the disclosure set forth in the Schedule 13D shall remain unchanged. Capitalized terms used but not otherwise defined in this Amendment shall have the meanings set forth in the Schedule 13D.

Item 4. Purpose of the Transaction

Item 4 of the Schedule 13D is hereby amended and supplemented as follows:

Between March 7, 2022 and March 24, 2022, the Reporting Person disposed of an aggregate of 393,297 ADSs, representing the equivalent of 23,597,820 Ordinary Shares, pursuant to the 10b5-1 Plan. On March 24, 2022, upon the disposition of all shares subject thereto, the 10b5-1 Plan terminated in accordance with it terms.

Item 5. Interest in Securities of the Issuer

Item 5 of the Schedule 13D is hereby amended and restated in its entirety by the following:

(a)–(b)  The Reporting Person is the beneficial owner of 238,105,533 Ordinary Shares of the Issuer evidenced bv 3,968,425 ADSs, representing approximately 9.9% of the outstanding Ordinary Shares of the Issuer based upon 2,406,874,578 Ordinary Shares, including Ordinary Shares evidenced by ADSs, outstanding as of December 31, 2021.

Except for the foregoing and the disposal of 136,703 ADSs, representing the equivalent of 8,202,180 Ordinary Shares, between March 2, 2022 through March 4, 2022 in a series of transactions pursuant to the 10b5-1 Plan at prices ranging from $0.7579 to $0.8202 per ADS as reported on the Reporting Person’s Amendment No. 6 to Schedule 13D filed on March 4, 2022, the Reporting Person has not effected any transactions in Ordinary Shares, including Ordinary Shares evidenced by ADSs, in the past 60 days.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: March 28, 2022

Schedule I

DIRECTORS AND EXECUTIVE OFFICERS LIFE BIOSCIENCES LLC

The operating agreement of Life Biosciences LLC (the “Company”) provides that the Company’s directors shall constitute the managers for purposes of the Delaware Limited Liability Company Act and shall have authority to delegate their day-to-day management responsibilities to one or more officers of the Company. The name, function, citizenship and present principal occupation or employment of each of the Company’s directors and executive officers are set forth below. Unless otherwise indicated below, (i) each occupation set forth opposite an individual’s name refers to employment with Life Biosciences Inc. and (ii) the business address of each director and executive officer of the Company is 75 Park Plaza, Level 3, Boston, MA 02116.